|
Q-1294
|
Thursday, June 11, 2026 |
With regard to the role of Health Canada, the Public Health Agency of Canada, and the government in the COVID-19 pandemic response: (a) what are the details of all analyses, briefing materials, evidence, or decision-making frameworks which supported the use of population-wide lockdown measures in the early stages of the COVID-19 pandemic, given that section 4.3 of Canadian Pandemic Influenza Preparedness: Planning Guidance for the Health Sector states that such measures are "impractical, if not impossible"; (b) did the Public Health Agency of Canada conduct formal documented risk assessments at the outset of the COVID-19 pandemic, including those described in section 3.5.2 of Canadian Pandemic Influenza Preparedness addressing (i) viral characteristics, (ii) anticipated or observed impacts on the healthcare system and community, (iii) affected age and risk groups, (iv) antiviral resistance, (v) estimated effectiveness of control measures, including any interim, preliminary, or continuously updated assessments, and, if not, why not; (c) if the answer to (b) is affirmative, for each assessment, was are the details, including the (i) title or identifier, (ii) date initiated, (iii) date completed, (iv) details on whether the assessment was documented in written form, (v) summary of the findings; (d) were the assessments referred to in (c) made public, and, if so, for each, what was the (i) date of release, (ii) method of communication, (iii) summary of information disclosed, including links, publication titles, or specific public releases where available, and if not, why not; (e) what evidence, analyses, or guidance informed the federal government's recommendations regarding (i) mass testing and contact tracing, (ii) quarantine of exposed individuals, (iii) border closures, (iv) border entry and exit screening, in light of the World Health Organization publication titled Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza, including any analyses or memoranda comparing Canadian measures to that guidance; (f) in the document titled Guidance for a strategic approach to lifting restrictive public health measures, how did the federal government define "significant population immunity", and what quantitative thresholds, models, indicators, or criteria were used to determine when restrictive public health measures would be lifted or maintained; (g) did the government conduct analyses to assess and quantify the potential impacts of restrictive public health measures, including health, economic, social, educational, and mental health impacts, including analyses conducted prior to or during implementation of such measures, and if so, for each analysis, (i) what is the date, (ii) what is the title, (iii) who is the responsible department, (iv) who is the approving authority, (v) what are the key findings, and if not, why not; (h) were the analyses referred to in (g) made public, and, if so, when and by what means, including links, publication titles, or specific public releases where available; if not, why not; (i) what categories of adverse impacts, including health, economic, and social effects, were considered in federal assessments of COVID-19 response measures, and how were these categories were incorporated into decision-making processes; (j) what federal programs or data sources were used to monitor (i) health outcomes, (ii) broader societal impacts associated with COVID-19 public health measures, including any reports, dashboards, or summaries produced from these data sources, and what were the key findings of those programs; (k) did officials within Health Canada, the Public Health Agency of Canada, central agencies, or the Prime Minister's Office review the July 2020 open letter titled Dealing with COVID-19 and, A Balanced Response, and if so, which officials reviewed it, how was it reviewed, and on what dates; (l) what consideration was given to the recommendations contained in the letter referenced in (k), including which recommendations, if any, were adopted or rejected, and the rationale for those decisions, including any written evaluations, summaries, or decision records assessing those recommendations; and (m) what are the details of all briefing notes, memoranda, or decision documents prepared for, or provided to, federal ministers, central agencies, or the Prime Minister's Office between January 1, 2020, and December 31, 2021 regarding COVID-19 public health measures, including but not limited to materials prepared by Health Canada, the Public Health Agency of Canada, or other federal departments, and including for each (i) title or subject, (ii) date, (iii) originating department or agency? |
Answered |
Monday, September 21, 2026 |
|
Q-1251
|
Tuesday, June 2, 2026 |
With regard to hospitality spending by Global Affairs Canada at properties owned by the Brookfield Corporation or its subsidiaries, including Brookfield Property Partners, since the current Prime Minister was sworn in on March 14, 2025: (a) what was the total amount spent at Brookfield-owned properties; (b) what is the name of each such property with expenditures by Global Affairs Canada and how much was spent at each property; and (c) what are the details of all hospitality expenditures at Brookfield properties, including, for each, the (i) date, (ii) amount, (iii) description of the goods or services, (iv) event description, (v) name of the property, (vi) location? |
Answered |
Monday, September 21, 2026 |
|
Q-1250
|
Tuesday, June 2, 2026 |
With regard to office or commercial spaces currently rented or leased by the government at properties owned by the Brookfield Corporation or its subsidiaries, including Brookfield Property Partners, broken down by department, agency or Crown corporation: what are the details of all such spaces, including the (i) location, (ii) address, (iii) square footage, (iv) purpose of the usage, (v) amount of monthly rent, (vi) date and amount of the last rent increase, (vii) start and end dates of the lease? |
Answered |
Monday, September 21, 2026 |
|
Q-1194
|
Monday, May 4, 2026 |
With regard to government agreements with Pfizer, broken down by department or agency, since January 1, 2019: (a) what is the total value of all federal funds transferred to Pfizer, broken down by year and by program under which they were transferred; (b) which of the funding agreements included non-disclosure or confidentiality provisions, and what is the length of time (15 years, lifetime, etc.) for the provisions associated with each agreement, broken down by department; (c) what are the details of each contract signed with Pfizer, including the (i) date, (ii) value, (iii) description, including the volume of goods or services, (iv) duration, (v) manner in which the contract was awarded (sole-sourced or competitive bid); and (d) what are the details of all sponsorship agreements that government entities have entered into with Pfizer, including, for each, the (i) date, (ii) amount of government funding, (iii) event description, (iv) location? |
Answered |
Monday, September 21, 2026 |
|
Q-991
|
Monday, March 23, 2026 |
With regard to Health Canada, the Public Health Agency of Canada and product recalls since 2018: (a) which sections or secretariats within Health Canada or the Public Health Agency of Canada decide if a product is recalled, and what are the details of each, including the number of employees and their titles; (b) what is the process for initiating a product recall, including who initiates the recall and the metric used to determine if a product should be recalled; (c) for each recall since 2018, (i) who initiated the recall, (ii) what was the reason for the recall, (iii) how were Canadians notified of the recall, (iv) what was the risk of injury from the product, (v) how many Canadians were injured from the product, (vi) how many Canadians died from the product, (vii) what was the product; and (d) are products recalled because of fraudulent claims, and, if so, (i) who is responsible for determining if a product made a fraudulent claim, (ii) what is the process used to determine if a claim is fraudulent, (iii) what are the penalties for a fraudulent claim, (iv) how many fraudulent claims were identified but the product wasn't recalled, (v) what is the product name and the date for each fraudulent claim in (d)(iv)? |
Answered |
Friday, May 8, 2026 |
|
Q-990
|
Monday, March 23, 2026 |
With regard to Health Canada's regulation of the modRNA COVID-19 vaccines: (a) what information does Health Canada possess on the identity of the facility or facilities responsible for manufacturing, linearizing and quality-controlling the plasmid DNA template used to produce mRNA for the authorized COVID-19 vaccines; (b) what inspections of the manufacturing facilities did Health Canada perform regarding manufacturing, testing and release of the linear DNA template that formed the starting material for the COVID-19 mRNA vaccines, and which manufacturers or vendors and sites were inspected, when and by whom; (c) if the inspections in (b) were not done, why not; (d) what quality assessment was performed with the sponsors (Pfizer Canada ULC or BioNTech SE) concerning the control of the linear DNA template, its plasmid source and the outsourcing of its production by (i) Canadian authorities, (ii) other regulators who shared the results with Canadian authorities; (e) did Health Canada determine if there were deficiencies, open questions or site qualifications related to the linear DNA template or plasmid manufacturing process, and, if so, what was the outcome, or, if not, why not; (f) were the linearization and residual DNA removal processes required to comply with standards in (i) ICH Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (with respect to residual DNA limits and characterization), (ii) ICH Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products, (iii) USP <1047> and <1049>: Gene Therapy Products and DNA Templates-Residual DNA Testing and Limits; (g) if the answer to (f) is negative, why not; (h) is Health Canada aware of any shared or outsourced master plasmid cell bank stock arrangements between (i) Pfizer and other entities, (ii) Moderna and other entities, to produce mRNA templates across multiple facilities or jurisdictions; (i) has Health Canada received any deviation reports, corrective and preventive action plans, or lot investigations relating to incomplete linearization in (i) Pfizer's, (ii) Moderna's, COVID-19 vaccine drug substance or finished product; and (j) if the answer to (i) is affirmative, what were the dates and findings of those reports, and were any product quality complaints or safety concerns escalated to the Biologic and Radiopharmaceutical Drugs Directorate? |
Answered |
Friday, May 8, 2026 |
|
Q-767
|
Thursday, January 22, 2026 |
With regard to Health Canada, the Public Health Agency of Canada, Innovation, Science and Economic Development Canada, reports of myocarditis and pericarditis following COVID-19 vaccination and the March 3, 2021, International Regulatory Meeting for Pharmacovigilance Cluster on myocarditis following COVID-19 vaccination, at which Canada was represented: (a) what data were provided at this meeting in relation to myocarditis and pericarditis reports; (b) who attended this meeting on behalf of Canada; (c) what was the conclusion of the cluster meeting and did Health Canada agree with this conclusion; (d) whether the answer to (c) is affirmative or negative, what was Health Canada's rationale; (e) following this meeting, (i) what was Health Canada's action plan, (ii) was there a plan to investigate this signal further by Health Canada or any other regulatory body, and, if so, when, by whom and what was the plan; (f) were there meetings between Health Canada and other international regulatory agencies and the Marketing Authorization Holder, and, if so, what terms and conditions were placed upon the vaccine companies by Health Canada in relation to the reports of myocarditis and pericarditis; (g) what actions were taken by Health Canada or the Public Health Agency of Canada to identify cases of myocarditis or pericarditis following COVID-19 immunization in Canada with respect to (i) diagnostic parameters, (ii) research, (iii) reporting from health care providers, (iv) provincial guidance; and (h) for communications regarding the risk of myocarditis and pericarditis following COVID-19 vaccination for the public, (i) what input from non-government organizations and institutions was considered for public and media communications and messaging, (ii) what were the dates of the communication, (iii) what strategies and media scripts were developed, (iv) where are these communications posted or archived, (v) how and when was guidance to health care professionals updated to ensure informed consent with respect to myocarditis and pericarditis following COVID-19 vaccination? |
Answered |
Wednesday, March 11, 2026 |
|
Q-766
|
Thursday, January 22, 2026 |
With regard to Health Canada, the Public Health Agency of Canada and reports of myocarditis and pericarditis following COVID-19 vaccination: (a) what is the standard operating procedure when an Adverse Event Following Immunization report containing a potential safety signal is received or identified; (b) what federal teams, working groups, contract companies and persons were responsible for requesting, receiving, reviewing and monitoring any Adverse Event Following Immunization reports with respect to myocarditis and pericarditis following the COVID-19 vaccines from (i) international sources, (ii) the provinces and territories; (c) after the information in (b) was received, what steps or actions were taken next, by whom, and on what date; (d) was the Public Health Agency of Canada or Health Canada notified of Adverse Event Following Immunization reports for myocarditis and pericarditis following COVID-19 vaccination, and, if so, for each notification, what was the (i) name of the notifier, (ii) title of the notifier, (iii) form of notification, (iv) name of the person who was notified, (v) date of the notification; (e) did the Public Health Agency of Canada or Health Canada receive the initial reports of myocarditis and pericarditis following COVID-19 vaccination from the Israeli Ministry of Health in February 2021, and, if so, (i) who received the notification, (ii) what was the date of the notification, (iii) what actions were taken after the notification, (iv) who authorized these actions, including their name, their title and the date of authorization; (f) for each communication between the Public Health Agency of Canada, Health Canada and all Public Health Agency of Canada or Health Canada COVID-19 task forces or working groups related to the Israeli Ministry of Health myocarditis and pericarditis safety signal notification, what was the (i) date, (ii) subject, (iii) type and content, of the communication; and (g) what communication related to the myocarditis and pericarditis safety signal occurred between the Public Health Agency of Canada, Health Canada or the Public Health Agency of Canada or Health Canada COVID-19 task forces and the COVID-19 vaccine manufacturer, including the (i) date, (ii) subject, (iii) type and content, of the communication? |
Answered |
Wednesday, March 11, 2026 |
